Oncology Clovis' Rubraca close to EU approval in ovarian cancer CHMP backs conditional approval for PARP drug
News AZ's cancer and respiratory drugs approved in Japan Two AstraZeneca (AZ) drugs have been approved in Japan – its cancer drug Lynparza and its respiratory drug Fasenra.
News AZ's Lynparza becomes first PARP drug approved in breast can... Lynparza first in class approved in breast cancer
News Clovis PARP drug gets fast US review in new ovarian cancer u... Impressed by survival data, FDA hastens review in expanded patient group
News Tesaro gets European approval on Zejula, set to challenge AZ Tesaro's PARP drug approved in wider ovarian cancer population
News MicroRNA diagnostic could be big advance in ovarian cancer AI blood test achieves very high accuracy and specificity for detecting ovarian cancer.
News Remepy's hybrid Parkinson's therapy poised for phase 3 Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
